Lenacapavir: A First-in-Class Capsid Inhibitor for Six-Monthly HIV Prevention and Treatment

1. Introduction: A New Class of Antiretroviral

For four decades, the pharmacological treatment and prevention of HIV-1 has been dominated by a small number of mechanistic classes: nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, integrase strand transfer inhibitors (INSTIs), and the entry and attachment inhibitors. Almost every one of these targets either a viral enzyme or the interaction between the viral envelope and a host receptor. Lenacapavir represents a genuinely new addition to this list: it is the first-in-class inhibitor of the HIV-1 capsid, the protein shell that packages the viral genome and orchestrates the earliest and latest steps of the viral life cycle.

Lenacapavir (developed by Gilead Sciences; brand name Sunlenca for treatment and Yeztugo for prevention) is notable for two reasons that are often conflated. First, it is a mechanistically novel agent that binds the p24 capsid protein rather than an enzyme. Second, it is administered as a subcutaneous injection every six months, which is the longest dosing interval of any approved antiretroviral to date. The combination of a new target and an extremely long dosing interval has generated intense interest in both the treatment of multidrug-resistant HIV and, more recently, the prevention of HIV acquisition.

This article separates what is firmly established — an approved treatment indication for multidrug-resistant HIV — from what has been reported more recently in the prevention field, where the data have moved quickly and where full peer review and final publication details should be verified as they become available. Throughout, we distinguish confirmed regulatory approvals from newly reported trial outcomes.

2. The HIV-1 Capsid as a Therapeutic Target

The HIV-1 capsid is a conical, fullerene-like shell built from several hundred copies of the p24 capsid (CA) protein, arranged into hexameric and pentameric units. Historically the capsid was viewed as a passive container, a structural scaffold that simply protected the viral RNA. Modern virology has overturned that view. The capsid is now understood to be a multifunctional machine that:

• shields the reverse-transcription complex from innate immune sensors such as cGAS, which would otherwise detect the viral DNA and trigger an interferon response;
• interacts with host nuclear-pore proteins (nucleoporins) to mediate capsid-dependent nuclear import of the pre-integration complex;
• coordinates the timed disassembly (uncoating) of the core at the point of integration; and
• participates in the late stages of assembly and the recruitment of host factors for particle release and maturation.

Because the capsid performs essential functions at both the beginning and the end of the replication cycle, it is an attractive drug target. In principle, a single molecule that disrupts capsid function can interfere with multiple, temporally separated steps, a property that is sometimes described as making lenacapavir a «multistage» inhibitor. This interference also has the theoretical advantage of being less easily bypassed by a single compensatory mutation than a target with only one function.

3. Mechanism of Action

Lenacapavir binds directly to the p24 capsid protein. The established mechanistic picture, derived largely from structural and in-vitro studies, is that the drug stabilizes abnormal capsid assemblies and thereby disrupts several distinct processes:

• Nuclear import. Lenacapavir interferes with the capsid’s ability to engage nucleoporins and traverse the nuclear pore, so the viral genome fails to reach the nucleus efficiently.
• Capsid assembly and disassembly. The drug distorts the normal curvature and lattice of the shell, producing defective or over-stabilized cores that cannot complete uncoating at the correct time or place.
• Late-cycle effects. Even when the early cycle is partially bypassed experimentally, defects in the production and maturation of progeny virions are observed.

The precise balance between these effects and their relative contribution to clinical antiviral activity remain areas of active investigation. What is established is that the drug has potent activity against HIV-1 in vitro and in vivo and that its binding site is distinct from that of any previously approved antiretroviral. Lenacapavir is reported to have activity against both HIV-1 and, in some assays, HIV-2, though HIV-2 is a rare clinical scenario and the clinical relevance there is limited. **[Marked for verification.]**

4. Pharmacokinetics and the Six-Monthly Dosing Schedule

Lenacapavir is formulated both as an oral tablet and as a long-acting subcutaneous injection. The approved treatment regimen uses an oral lead-in (tablets taken over the first days of therapy) followed by a subcutaneous loading dose and then maintenance injections every six months. The exceptionally long interval is made possible by the drug’s high potency, its slow absorption from the subcutaneous depot, and a pharmacokinetic profile that yields sustained plasma concentrations well above the protein-adjusted 95% inhibitory concentration for an extended period.

From a clinical-delivery perspective, a six-monthly injection is transformative. Adherence to daily oral antiretrovirals is a persistent challenge, particularly for prevention, and long-acting agents shift the adherence burden from daily self-administration to intermittent clinic visits. This is the same logic that drove the development of long-acting cabotegravir, but lenacapavir extends the interval from every one to two months to every six months.

Practical constraints remain. Correct subcutaneous injection technique is required, and the injection volumes are not trivial, which means administration should be performed by trained personnel. There is currently no long-acting oral equivalent for patients who wish to stop injection therapy, and the prolonged pharmacokinetic «tail» means that a missed dose cannot simply be reversed; drug exposure may persist at subtherapeutic levels for a period after discontinuation, with implications for resistance if viremia is not controlled. **[Marked for verification.]**

5. Treatment Indication: CAPELLA and Multidrug-Resistant HIV

The first established clinical use of lenacapavir is in heavily treatment-experienced adults living with multidrug-resistant HIV-1 whose current regimen is failing. The supporting study, CAPELLA, was a phase 2/3 trial in this difficult-to-treat population. CAPELLA enrolled participants with resistance to multiple antiretroviral classes and compared lenacapavir, added to an optimized background regimen selected by the investigator, against a placebo-plus-optimized-background control phase, followed by open-label extension.

The trial reported that a substantial majority of participants achieved and maintained virologic suppression (HIV-1 RNA below 50 copies/mL) over the extended follow-up, together with meaningful CD4 cell count increases. These results were presented at international conferences and subsequently published in a major peer-reviewed journal in 2023; the specific numerical outcomes, subgroup analyses, and the exact publication citation should be verified against the primary paper. **[Citation details to be verified.]** The FDA approval for treatment was based principally on this evidence.

The clinical significance of CAPELLA lies in the population studied. Patients with multidrug-resistant HIV and limited remaining treatment options historically had few paths to durable suppression. A mechanistically novel agent with a completely different resistance profile offers the possibility of constructing a functional regimen when conventional options have been exhausted. This is the setting in which lenacapavir is unambiguously established and indicated, in combination with other active antiretrovirals.

6. Prevention: The PURPOSE Clinical Program

The prevention program for lenacapavir — the PURPOSE family of trials — is the reason the drug has attracted global attention. The program spans multiple populations at risk of HIV acquisition and is designed to test whether six-monthly lenacapavir can reduce incident HIV infection when used as pre-exposure prophylaxis (PrEP). It is essential to describe these results as trial-reported outcomes and to recognize that peer-reviewed publication and independent replication are the standard by which they should finally be judged.

6.1. PURPOSE 1

PURPOSE 1 evaluated lenacapavir for PrEP among cisgender women and adolescent girls in South Africa and Uganda, comparing lenacapavir injections with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and with background HIV incidence. When the results were first reported in 2024, the lenacapavir arm was described as having zero incident HIV infections among the participants who received it, corresponding in that analysis to 100% efficacy relative to the background incidence in the enrolled communities. This outcome generated widespread coverage. The reasons for the exceptionally favorable result are debated: in addition to the drug’s potency, the absolute number of events was low, the trial’s design and the background-incidence comparison differ from a head-to-head design, and adherence in the oral comparator arm is known to be a factor in such trials. The trial was subsequently published; the exact citation and each numerical endpoint should be verified. **[Citation details to be verified.]**

6.2. PURPOSE 2

PURPOSE 2 evaluated lenacapavir among cisgender men, transgender men and women, and gender-diverse individuals who have sex with men across multiple countries. Reported in 2025, the trial described a large relative reduction in HIV incidence, widely communicated as approximately 96%, compared with the daily oral FTC/TDF comparator. Again, the result was described with remarkable consistency across sites and was not associated with the adherence-dependent variability seen with oral PrEP. As with PURPOSE 1, the figures circulated at announcement are those reported by the sponsor and investigators; the definitive endpoints and publication details require verification from the peer-reviewed report. **[Citation details to be verified.]**

6.3. Broader PURPOSE Program

Additional arms and trials in the PURPOSE program were designed to address other populations, including people who inject drugs, serodifferent couples, and broader heterosexual populations in different geographies. These have been described in trial registries and sponsor communications. Because several were ongoing as the prevention results emerged, their final outcomes should be treated as evolving. **[Marked for verification.]**

7. Safety and the Injection-Site Profile

Across the treatment and prevention trials, lenacapavir has generally been well tolerated. The most characteristic adverse effects are local: injection-site nodules, swelling, pain, and erythema at the subcutaneous administration site. These are largely attributable to the depot formulation rather than to systemic toxicity, and they are typically mild to moderate and self-limited, though their cumulative frequency over many years of repeated dosing is a legitimate consideration.

Systemic adverse events reported have not, to date, revealed a dominant class-specific toxicity, which distinguishes lenacapavir from some earlier classes. Nonetheless, long-term safety data beyond a few years remain limited relative to older antiretroviral classes, and post-marketing surveillance will be important as use expands, particularly if the drug is deployed at scale in healthy populations for prevention, where the tolerance for adverse effects is lower than in treatment. No drug interactions of the magnitude seen with some older agents have dominated the field, but the interaction profile continues to be characterized. **[Marked for verification.]**

8. Resistance Profile

Because the capsid is a new target, resistance to lenacapavir is expected to arise through mutations in the gag capsid region rather than through the familiar reverse transcriptase, protease, or integrase pathways. Specific substitutions in the capsid protein have been identified in vitro and in some participants with virologic failure on lenacapavir-containing regimens. Two features are important:

• Lack of cross-resistance with existing classes. Capsid mutations would not be expected to confer resistance to INSTIs, NRTIs, or protease inhibitors, and vice versa. This is the principal reason lenacapavir is valuable in multidrug-resistant disease.
• Within-class cross-resistance. Because lenacapavir is the first capsid inhibitor, cross-resistance to future capsid inhibitors is a theoretical concern and will depend on whether mutations overlap with their binding sites.

The emergence of capsid mutations under drug pressure, and their associated fitness costs, are active research questions. As with all antiretrovirals, lenacapavir should be used in combination with other fully active agents to reduce the probability of resistance. The precise mutational pathways and their clinical frequency should be verified against resistance databases and primary literature. **[Marked for verification.]**

9. Comparison with Cabotegravir Long-Acting

Lenacapavir is frequently compared with long-acting cabotegravir (CAB-LA; brand Apretude for prevention and Vocabria/CABENUVA for treatment), an integrase inhibitor given every one to two months. The two agents embody different mechanistic classes and different dosing cadences. The table below summarizes the principal contrasts; numerical efficacy figures should be read alongside their respective trial designs.

The six-monthly interval is the practical advantage of lenacapavir: fewer clinic visits and less frequent injections may improve acceptability and coverage, particularly where health systems are strained. The counterweights are the requirement for reliable cold chain and injection logistics, the absence of an oral «exit» strategy, and the fact that the prevention evidence, while striking, is more recent. Cabotegravir, by contrast, has accumulated more years of real-world prevention and treatment experience. Both agents illustrate the broader shift away from daily oral therapy.

10. Regulatory Status, WHO Guidance, and Global Access

The regulatory story has unfolded in distinct phases, and these must not be blurred:

• Treatment approval (2022). The FDA approved lenacapavir (Sunlenca) in December 2022 for multidrug-resistant HIV-1 in heavily treatment-experienced adults, in combination with other antiretrovirals, based on CAPELLA. This is the established, confirmed indication.
• Prevention approval (2025). Following the PURPOSE results, lenacapavir was approved by the FDA for HIV prevention under the brand Yeztugo in June 2025. This transitioned the prevention indication from trial-reported outcome to approved label; readers should confirm the precise date and label wording. **[Marked for verification.]**
• Other regulators. Approvals and reviews by the European Medicines Agency and national authorities have proceeded on their own timelines; these should be verified individually. **[Marked for verification.]**

10.1. WHO Recommendations

The World Health Organization issued guidance on lenacapavir for HIV prevention following the PURPOSE data, positioning it as an additional prevention option. WHO recommendations in this field typically depend on regulatory status, on programmatic feasibility, and on affordability, and they are periodically updated. The exact wording, date, and target populations of the WHO recommendation should be verified against the current published guideline. **[Marked for verification.]**

10.2. Licensing and Generic Access

Access is the central equity question for any high-cost, high-profile antiretroviral. In October 2024, Gilead announced voluntary licensing agreements, coordinated through the Medicines Patent Pool (MPP), intended to allow generic manufacturers to produce and supply generic lenacapavir for a defined set of low- and lower-middle-income countries. The geographic scope of such licenses is always the crux: the number of countries included, whether upper-middle-income countries with substantial HIV burden are covered, and the royalty structure all determine real-world impact. The MPP is a UN-backed organization whose mission is exactly this kind of technology transfer. Details of the license terms and the list of sublicensees should be verified. **[Marked for verification.]**

The tension between a highly effective but expensive product and the populations that need it most — particularly in sub-Saharan Africa, where the prevention trials were conducted — is a recurring theme in HIV. That the PURPOSE trials enrolled participants in exactly the regions where access is most constrained makes the licensing question ethically salient, and it will remain a test case for how novel antiretrovirals are priced and distributed.

11. Conclusion

Lenacapavir is a genuine scientific advance on two axes. Mechanistically, it is the first capsid inhibitor to reach clinical use, binding the p24 capsid protein and disrupting capsid-mediated nuclear import, capsid assembly, and disassembly — a multistage mechanism with no cross-resistance to existing antiretroviral classes. Practically, its six-monthly subcutaneous dosing is the longest interval of any approved antiretroviral, and it has demonstrated potent antiviral activity in multidrug-resistant treatment and, in the PURPOSE program, in prevention.

The established facts are the 2022 FDA treatment approval based on CAPELLA. The prevention results from PURPOSE 1 and PURPOSE 2, reported in 2024 and 2025, are extremely encouraging — including the widely cited zero-infection and approximately 96% reduction figures — but they are recent, and their definitive peer-reviewed details, as well as the precise regulatory and WHO milestones, should be verified as primary sources become available. The unresolved questions are the long-term durability of protection, the emergence of capsid resistance, the cumulative tolerability of repeated injections over many years, and whether generic licensing will translate into broad, affordable access. If those questions are answered favorably, lenacapavir may mark a shift from daily pills to infrequent, highly effective long-acting regimens for both prevention and treatment.

Sources and Key Research Centers

1. National Institute of Allergy and Infectious Diseases (NIAID), NIH — The principal U.S. funder of HIV research, including basic capsid biology and clinical trial networks that underpin long-acting antiretroviral development.
2. U.S. Food and Drug Administration (FDA) — Regulatory authority that approved lenacapavir (Sunlenca) in December 2022 for multidrug-resistant HIV treatment and later for prevention; source of the approved label and prescribing information.
3. World Health Organization (WHO) — Issues global guidance on HIV prevention and treatment and on the introduction of new antiretrovirals into national programs.
4. U.S. Centers for Disease Control and Prevention (CDC), Division of HIV Prevention — U.S. public-health guidance on HIV prevention, including pre-exposure prophylaxis and long-acting options.
5. Joint United Nations Programme on HIV/AIDS (UNAIDS) — Global epidemiology and access advocacy; tracks the introduction and affordability of new prevention technologies.
6. Medicines Patent Pool (MPP) — UN-backed organization coordinating voluntary licensing to enable generic production and affordable access in low- and middle-income countries.
7. Gilead Sciences — Developer and sponsor of lenacapavir and the CAPELLA and PURPOSE clinical programs; source of trial announcements (to be read alongside peer-reviewed publications).
8. ClinicalTrials.gov (U.S. National Library of Medicine) — Registry of the CAPELLA and PURPOSE trials; search terms: lenacapavir, capsid inhibitor, PURPOSE, CAPELLA.
9. The New England Journal of Medicine — Peer-reviewed journal publishing key CAPELLA and PURPOSE trial reports; consult the primary papers for exact endpoints and citations. **[Citation details to be verified.]**
10. International AIDS Society (IAS) — Professional society convening the International AIDS Conference and HIV Science meetings where central lenacapavir data have been presented.